Race and appointment availability are significant predictors for the continuity of care among patients with chronic inflammatory skin disease.

Incyte CEO Hervé Hoppenot has promised investors that 2025 will be “a year that will be full of many defining catalysts” for ...

Cryotherapy, often called "cold therapy," is gaining popularity for its potential health benefits, ranging from pain relief ...

The following is a summary of “Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients ...

Shares of Kymera Therapeutics (NASDAQ:KYMR) spiked on Tuesday after the developer of oral protein degraders outlined its 2025 ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.

Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Increased eczema risks in certain populations were associated with moderately high calcium intake, although pregnant women ...

Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin. Maurer was an author ...